An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid

Neuroscience Letters

Volumn 409, Issue 3, 2006, Pages 215-219

  Portelius, Erik ^a   Zetterberg, Henrik ^a   Andreasson, Ulf ^a   Brinkmalm, Gunnar ^c   Andreasen, Niels ^b   Wallin, Anders ^a   Westman Brinkmalm, Ann ^a   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

A fragment signature; Alzheimer's disease; Cerebrospinal fluid; MALDI TOFMS

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42];

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOPRECIPITATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; TIME OF FLIGHT MASS SPECTROMETRY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS;

EID: 33750441499     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.09.044     Document Type: Article

References (24)

1. Allinson T.M., Parkin E.T., Turner A.J., and Hooper N.M. ADAMs family members as amyloid precursor protein alpha-secretases. J. Neurosci. Res. 74 (2003) 342-352
2. Andreasen N., Hesse C., Davidsson P., Minthon L., Wallin A., Winblad B., Vanderstichele H., Vanmechelen E., and Blennow K. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 56 (1999) 673-680
3. Beher D., Wrigley J.D., Owens A.P., and Shearman M.S. Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. J. Neurochem. 82 (2002) 563-575
4. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
5. Blennow K., and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2 (2003) 605-613
6. Eckman E.A., and Eckman C.B. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 33 (2005) 1101-1105
7. Eckman E.A., Reed D.K., and Eckman C.B. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J. Biol. Chem. 276 (2001) 24540-24548
8. Eriksson L., Johansson E., and Wold S. QSAR model validation. In: Chen F., and Scüürmann G. (Eds). Quantitative Structure-Activity Relationships in Environmental Sciences vol. VII (1996), SETAC Press, Florida, Elsinore, Denmark 381-397
9. Gowing E., Roher A.E., Woods A.S., Cotter R.J., Chaney M., Little S.P., and Ball M.J. Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J. Biol. Chem. 269 (1994) 10987-10990
10. Higgins L.S., Murphy Jr. G.M., Forno L.S., Catalano R., and Cordell B. P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Am. J. Pathol. 149 (1996) 585-596
11. Lalowski M., Golabek A., Lemere C.A., Selkoe D.J., Wisniewski H.M., Beavis R.C., Frangione B., and Wisniewski T. The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J. Biol. Chem. 271 (1996) 33623-33631
12. Leissring M.A., Lu A., Condron M.M., Teplow D.B., Stein R.L., Farris W., and Selkoe D.J. Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J. Biol. Chem. 278 (2003) 37314-37320
13. Lindgren F., Hansen B., Karcher W., Sjöström M., and Eriksson L. Model validation by permutation tests: applications to variable selection. J. Chemom. 10 (1996) 521-532
14. Maddalena A.S., Papassotiropoulos A., Gonzalez-Agosti C., Signorell A., Hegi T., Pasch T., Nitsch R.M., and Hock C. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. Neurodegenerative Dis. 1 (2004) 231-235
15. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984) 939-944
16. Portelius E., Westman-Brinkmalm A., Zetterberg H., and Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res. 5 (2006) 1010-1016
17. Sahasrabudhe S.R., Spruyt M.A., Muenkel H.A., Blume A.J., Vitek M.P., and Jacobsen J.S. Release of amino-terminal fragments from amyloid precursor protein reporter and mutated derivatives in cultured cells. J. Biol. Chem. 267 (1992) 25602-25608
18. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
19. Selkoe D.J., and Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 545-584
20. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., McCormack R., Wolfert R., Selkoe D., Lieberburg I., and Schenk D. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 (1992) 325-327
21. Sisodia S.S. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 6075-6079
22. Tomlinson B.E., Blessed G., and Roth M. Observations on the brains of non-demented old people. J. Neurol. Sci. 7 (1968) 331-356
23. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., and Schenk D.B. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61 (1993) 1965-1968
24. Wiltfang J., Esselmann H., Bibl M., Smirnov A., Otto M., Paul S., Schmidt B., Klafki H.W., Maler M., Dyrks T., Bienert M., Beyermann M., Ruther E., and Kornhuber J. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 81 (2002) 481-496